Eli Lilly's experimental weight loss drug shed 21% of body weight in diabetes trial
- New studies published in The Lancet and the New England Journal of Medicine show Eli Lilly's experimental drug retatrutide leads to meaningful weight loss in patients with Type 2 diabetes and obesity.
- Unlike existing GLP-1 drugs, retatrutide acts as a triple agonist by targeting three metabolic hormone receptors—GLP-1, GIP, and glucagon—to manage appetite and blood sugar while accelerating metabolism.
- Trial results indicate patients with Type 2 diabetes lost up to 60 pounds, or about 23% of their body weight, while those without diabetes lost up to 70 pounds, or 25% of their body weight, after 80 weeks.
- Beyond weight reduction, the drug improved blood sugar control and helped patients with obstructive sleep apnea and knee arthritis; Dr. Susan Spratt of Duke Health called it "truly an advance in diabetes care."
- Eli Lilly plans to file for approval with the Food and Drug Administration early next year, though researchers noted the trials lacked head-to-head comparisons with other existing obesity medications.
66 Articles
66 Articles
New investigational drug delivers up to 23.3% weight loss in people with obesity and diabetes
New data from a phase 2b study being presented at the 2026 annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2), show that, for people living with obesity and type 2 diabetes, treatment with Eli Lilly's new investigational medication, EloraTZP, a combination of eloralintide and tirzepatide (TZP), resulted in weight loss of up to 23.3% at the maximum dose and accompanying substantial improv…
Eli Lilly Diabetes Drug Spurs Record Weight Loss in Trials
A new entrant in the weight-loss drug race just posted eye-catching numbers. NBC News reports that Eli Lilly's experimental shot retatrutide helped people with Type 2 diabetesshed as much as 60 pounds—about 23% of their body weight—over 80 weeks, according to late-stage trial results in the Lancet...
Lilly Just Reported More Than Half of Patients on Its New Weight Loss Drug Lost 20% of Their Body Weight — and a Third Lost 25%. Here's How the News Could Shake Up the Obesity Drug Market.
Phase three trials on Eli Lilly's new weight loss drug, TRIUMPH-2, showed strong results.
Coverage Details
Bias Distribution
- 51% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
